Whalesbook
Zydus Lifesciences ka dhamaka! ₹11,000 Crore Ka Buyback aur US mein Acquisition!
Zydus Lifesciences ne Q4 FY26 ke results announce kiye hain aur bhai, numbers dekhne layak hain. Unki total income 16.2% jump kar ke ₹75,870 million ho gayi hai. Aur haan, net profit bhi 8.7% badh kar ₹12,725 million pahunch gaya hai. Iske saath hi, company ne ek zabardast move lete hue ₹11,000 million ka share buyback bhi approve kiya hai aur US mein Assertio Holdings Inc. ko bhi acquire kar rahe hain. Ye sab dekh kar lagta hai Zydus apne investors ko khush karna chahti hai!
Numbers aur Deals ki Kahani
Company ka EBITDA bhi 20.2% badha hai aur ₹25,544 million par pahuncha hai. Ye growth alag-alag business segments mein acchi performance ki wajah se hui hai. Aur jo ye US mein Assertio Holdings Inc. ko US$166 million mein acquire kar rahe hain, yeh ek strategic move hai. Isse Zydus ki US ki specialty aur oncology supportive-care markets mein presence aur mazboot hogi. Ye deal unka revenue diversify karegi aur global portfolio bhi strong karegi. Zydus pehle bhi US mein do specialty pharma companies ko 2022 mein acquire kar chuka hai, aur unka focus North America market par hamesha se raha hai.
Buyback aur Future Plans
Ye jo ₹11,000 million ka buyback approve hua hai, jisme woh ₹1,150 per share de rahe hain, yeh dikhata hai ki management ko apni company ke future par full bharosa hai. Isse shareholder returns badhenge aur EPS bhi improve ho sakta hai. Dusre players jaise Sun Pharma ka revenue 7.4% aur Dr. Reddy's ka 10.4% badha hai, jabki Zydus ka 16.2% ka growth aur yeh acquisition dikhata hai ki Zydus market mein proactive hai.
Kya Track Karein Aage?
Ab investors ko ye dekhna hoga ki ye acquisition kab tak poora hota hai aur Assertio Holdings ka integration kaise hota hai. Naye products aur biosimilars ka performance bhi track karna hoga. Aur ye buyback program kaise execute hota hai, yeh bhi important hoga. Company ka Net Debt to EBITDA Ratio ab 0.50x hai aur Net Debt ₹43,050 million hai.